Anti-inflammatory effect of the serratiopeptidase -rationale or fashionable: A study in rat paw oedema model induced by the carrageenan

Indian Journal of Physiology and Pharmacology

Volumn 56, Issue 4, 2012, Pages 367-374

  Joshi, Kalpesh K ^a,b   Nerurkar, Rajan P ^a,b  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Analgesic; Anti inflammatory drugs; Enzyme; Rational use of drugs

Indexed keywords

CARRAGEENAN; DICLOFENAC; SERRATIOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; MONOTHERAPY; NONHUMAN; PAW EDEMA; RAT; SCORING SYSTEM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; DICLOFENAC; DRUG COSTS; DRUG THERAPY, COMBINATION; EDEMA; EXTREMITIES; FEMALE; MALE; PEPTIDE HYDROLASES; RATS; RATS, WISTAR;

EID: 84871000517     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nakahama K, Yoshimura K, Marumoto R, Kikuchi M, Lee IS, Hase T et al. Cloning and sequencing of Serratia protease gene. Nucleic Acids Res 1986; 14 (14): 5843-5855.
2. Watne AL, Montgomery RL, Pettit WW. Enzymes Proposed as systemic annti-inflammatory agents. JAMA 1964; 188(10): 875-76.
3. [No Authors listed]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on 18-10-2011.
4. [No Authors listed]. http://www.ema.europa.euema/index.jsp?curl=pages%2Fincludes%2Fmedicines%2Fmedicines_landing_page.jsp&searchkwByEnter=true&quickSearch=serratiopeptidase. Accessed on 18-10-2011.
5. Sweetman SC. Supplementary Drugs and other Substances In Martindale -The Complete Drug Reference, 34th edition, Great Britain, Pharmaceutical Press, 2005; 1645-1766.
6. [No Authors listed]. United States Pharmacopeia: United States. First Asian Edition: Effective since 1st July 2002, Rockville, MD, United states.
7. [No Authors listed]. British National Formulary (2001), London: 'British Medical Association and The Royal Pharmaceutical Society of Great Britain' September, 2004.
8. [No Authors listed]. Indian Pharmacopeia. Government of India: Ministry of Health and welfare Published by Controller of publishers, New Delhi, volume 2.
9. th edition, McGraw Hill publications, New - York, 2006; pp. 671-771.
10. GH Vogel. Anti-inflammatory agents In Drug Discovery andevaluation-pharmacological Assays, II edition, Springer-Verlag, New-York, 2002; 759-765.
11. Malshe PC. Orally administered serratiopeptidase: can it work? J Assoc Physicians India 1998; 46 (5): 492.
12. Tsume Y, Taki Y, Sakane T, Nadai T, Sezaki H, Watabe K et al. Quantitative evaluation of the gastrointestinal absorption of protein into the blood and lymph circulation. Biol Pharm Bull 1996; 19 (10): 1332-1337.
13. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 1997; 273 (1 Pt 1): G139-G146.
14. Shilpa P. Jadav, Nilesh H. Patel, Tarang G. Shah, Maganlal V. Gajera, Hiren R. Trivedi, Bharat K. Shah. Comparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino rats. J Pharmacol Pharmacother 2010; 1 (2): 116-117.
15. Ishihara Y, Kitamura S, Takaku F. Experimental studies on distribution of cefotiam, a new betalactam antibiotic, in the lung and trachea of rabbits. II. Combined effects with serratiopeptidase. Jpn J Antibiot 1983; 36 (10): 2665-2570.
16. [No Authors listed]. Accessed on 18-10-2011. http://www.medicine.ox.ac.uk/bandolier/booth/alternat/serrapep.html
17. [No Authors listed]. http://vm.cfsan.fda.gov/~lrd/fr000106.html,homepage: http://www.fda.gov, A notice issued by FDA for marketing of 'Serrepeptase' at website: 'http://www.physicianformulas.com' 20th march, 2006.
18. Bharat Mahajan, RP Nerurkar. "Evaluation of prescribing trends & rationalitly of use of oral proteolytic enzymes." A dissertation submitted to University of Mumbai, Jan 2006.
19. [No Authors listed]. Accessed on 22-10-2011. http://www.mims.com/India/drug/search/.